NCT04570423 2026-02-18A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapySpectrum Pharmaceuticals, IncPhase 2 Recruiting40 enrolled